Total Payments
$171,630
2024 Payments
$45,905
Companies
18
Transactions
176
Medicare Patients
1,614
Medicare Billing
$177,541
Payment Breakdown by Category
Consulting$125,527 (73.1%)
Research$17,446 (10.2%)
Travel$12,182 (7.1%)
Other$11,615 (6.8%)
Food & Beverage$4,859 (2.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Consulting Fee | $125,527 | 44 | 73.1% |
| Unspecified | $17,446 | 1 | 10.2% |
| Travel and Lodging | $12,182 | 49 | 7.1% |
| Honoraria | $7,655 | 5 | 4.5% |
| Food and Beverage | $4,859 | 76 | 2.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $3,960 | 1 | 2.3% |
Payments by Type
General
$154,183
175 transactions
Research
$17,446
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Alexion Pharmaceuticals, Inc. | $92,903 | 100 | $0 (2024) |
| ARGENX US, INC. | $18,067 | 22 | $0 (2024) |
| Amgen Inc. | $16,070 | 14 | $0 (2024) |
| UCB SA | $10,863 | 3 | $0 (2024) |
| Takeda Pharmaceuticals U.S.A., Inc. | $9,464 | 10 | $0 (2024) |
| UCB, Inc. | $6,998 | 8 | $0 (2024) |
| Lundbeck LLC | $4,814 | 6 | $0 (2017) |
| Janssen Biotech, Inc. | $3,815 | 1 | $0 (2024) |
| CATALYST PHARMACEUTICALS, INC. | $2,525 | 3 | $0 (2020) |
| Horizon Therapeutics plc | $1,800 | 1 | $0 (2022) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $45,905 | 38 | Amgen Inc. ($13,070) |
| 2023 | $10,642 | 17 | ARGENX US, INC. ($5,561) |
| 2022 | $34,541 | 32 | Alexion Pharmaceuticals, Inc. ($13,196) |
| 2021 | $5,088 | 2 | UCB, Inc. ($5,088) |
| 2020 | $4,681 | 5 | CATALYST PHARMACEUTICALS, INC. ($2,500) |
| 2019 | $26,311 | 20 | Alexion Pharmaceuticals, Inc. ($26,286) |
| 2018 | $17,180 | 23 | Alexion Pharmaceuticals, Inc. ($17,180) |
| 2017 | $27,283 | 39 | Alexion Pharmaceuticals, Inc. ($22,470) |
All Payment Transactions
176 individual payment records from CMS Open Payments — Page 1 of 8
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 12/13/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $4.13 | General |
| 12/05/2024 | Janssen Global Services, LLC | — | Consulting Fee | Cash or cash equivalent | $1,110.00 | General |
| 10/30/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $4,720.00 | General |
| Category: Rare Disease | ||||||
| 10/26/2024 | Merck KGaA | — | Food and Beverage | In-kind items and services | $22.82 | General |
| 10/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Consulting Fee | Cash or cash equivalent | $4,950.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Travel and Lodging | In-kind items and services | $239.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $50.00 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/18/2024 | Amgen Inc. | UPLIZNA (Biological) | Food and Beverage | In-kind items and services | $21.36 | General |
| Category: Inflammation/Rare Disease | ||||||
| 10/17/2024 | UCB, Inc. | — | Food and Beverage | In-kind items and services | $16.25 | General |
| 10/16/2024 | ARGENX US, INC. | VYVGART (Drug) | Food and Beverage | In-kind items and services | $3.01 | General |
| Category: Immunology | ||||||
| 10/13/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Travel and Lodging | In-kind items and services | $280.85 | General |
| Category: Rare Disease | ||||||
| 10/11/2024 | Janssen Scientific Affairs, LLC | — | Consulting Fee | Cash or cash equivalent | $1,090.00 | General |
| 10/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Consulting Fee | Cash or cash equivalent | $8,356.50 | General |
| 10/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $55.93 | General |
| 10/03/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $52.95 | General |
| 09/23/2024 | Alexion Pharmaceuticals, Inc. | ULTOMIRIS (Biological) | Consulting Fee | Cash or cash equivalent | $5,310.00 | General |
| Category: Rare Disease | ||||||
| 08/27/2024 | UCB, Inc. | Rystiggo (Drug) | Consulting Fee | Cash or cash equivalent | $1,600.00 | General |
| Category: Neurology | ||||||
| 08/19/2024 | Janssen Biotech, Inc. | — | Consulting Fee | Cash or cash equivalent | $3,815.00 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $608.20 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Travel and Lodging | In-kind items and services | $238.26 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $50.00 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $35.00 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $30.00 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $22.06 | General |
| 07/27/2024 | Takeda Pharmaceuticals U.S.A., Inc. | — | Food and Beverage | In-kind items and services | $14.99 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| Safety and Efficacy Study of Ravulizumab in Adults With Generalized Myasthenia Gravis | Alexion Pharmaceuticals, Inc. | $17,446 | 1 |
Medicare Billing by Year
| Year | Procedures | Beneficiaries | Services | Submitted | Medicare Paid |
|---|---|---|---|---|---|
| 2023 | 9 | 355 | 467 | $279,793 | $43,527 |
| 2022 | 11 | 428 | 568 | $462,343 | $48,883 |
| 2021 | 10 | 399 | 524 | $449,397 | $49,048 |
| 2020 | 11 | 432 | 552 | $409,353 | $36,082 |
Total Patients
1,614
Total Services
2,111
Medicare Billing
$177,541
Procedure Codes
42
All Medicare Procedures & Services
42 procedure records from CMS Medicare Utilization — Page 1 of 2
| HCPCS | Description | Setting | Year | Patients | Services | Charges | Medicare Paid | Ratio |
|---|---|---|---|---|---|---|---|---|
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2023 | 112 | 166 | $69,390 | $19,995 | 28.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2023 | 75 | 102 | $46,948 | $8,628 | 18.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2023 | 47 | 47 | $13,461 | $7,697 | 57.2% |
| 99223 | Initial hospital care with moderate level of medical decision making, if using time, at least 75 minutes | Facility | 2023 | 12 | 13 | $9,841 | $2,079 | 21.1% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2023 | 35 | 52 | $13,572 | $1,479 | 10.9% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2023 | 12 | 12 | $109,350 | $1,169 | 1.1% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2023 | 15 | 17 | $5,985 | $915.00 | 15.3% |
| 95924 | Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | Facility | 2023 | 13 | 13 | $6,152 | $846.13 | 13.8% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2023 | 34 | 45 | $5,094 | $718.28 | 14.1% |
| 99215 | Established patient office or other outpatient visit, 40-54 minutes | Facility | 2022 | 121 | 185 | $84,042 | $21,690 | 25.8% |
| 99214 | Established patient office or other outpatient visit, 30-39 minutes | Facility | 2022 | 79 | 107 | $60,628 | $8,706 | 14.4% |
| 99205 | New patient office or other outpatient visit, 60-74 minutes | Facility | 2022 | 46 | 46 | $13,184 | $6,923 | 52.5% |
| 95910 | Nerve conduction, 7-8 studies | Facility | 2022 | 22 | 22 | $140,006 | $2,204 | 1.6% |
| 95911 | Nerve conduction, 9-10 studies | Facility | 2022 | 16 | 16 | $121,532 | $1,838 | 1.5% |
| 99233 | Follow-up hospital inpatient care per day, typically 35 minutes | Facility | 2022 | 11 | 19 | $6,992 | $1,783 | 25.5% |
| 95924 | Testing of autonomic (sympathetic and parasympathetic) nervous system function, at least 5 minutes of tilt | Facility | 2022 | 20 | 20 | $7,970 | $1,611 | 20.2% |
| G2212 | Prolonged office or other outpatient evaluation and management service(s) beyond the maximum required time of the primary procedure which has been selected using total time on the date of the primary service; each additional 15 minutes by the physician or | Facility | 2022 | 34 | 51 | $13,311 | $1,435 | 10.8% |
| 95885 | Needle measurement of electrical activity in arm or leg muscles, limited study | Facility | 2022 | 47 | 70 | $6,503 | $1,180 | 18.1% |
| 95923 | Testing of autonomic (sympathetic) nervous system function | Facility | 2022 | 19 | 19 | $4,076 | $795.58 | 19.5% |
| 99213 | Established patient office or other outpatient visit, 20-29 minutes | Facility | 2022 | 13 | 13 | $4,099 | $717.82 | 17.5% |
| 99215 | Established patient outpatient visit, total time 40-54 minutes | Facility | 2021 | 123 | 206 | $98,886 | $25,463 | 25.7% |
| 99214 | Established patient outpatient visit, total time 30-39 minutes | Facility | 2021 | 75 | 100 | $53,800 | $8,119 | 15.1% |
| 99205 | New patient outpatient visit, total time 60-74 minutes | Facility | 2021 | 33 | 33 | $12,132 | $5,638 | 46.5% |
| 95911 | Nerve transmission studies, 9-10 studies | Facility | 2021 | 22 | 22 | $161,084 | $2,680 | 1.7% |
| 95924 | Testing of autonomic (sympathetic) nervous system function, at least 5 minutes of tilt | Facility | 2021 | 28 | 28 | $10,752 | $2,128 | 19.8% |
About Dr. Srikanth Muppidi, MD
Dr. Srikanth Muppidi, MD is a Neuromuscular Medicine healthcare provider based in Stanford, California. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 10/24/2007. The National Provider Identifier (NPI) number assigned to this provider is 1568641736.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Dr. Srikanth Muppidi, MD has received a total of $171,630 in payments from pharmaceutical and medical device companies, with $45,905 received in 2024. These payments were reported across 176 transactions from 18 companies. The most common payment nature is "Consulting Fee" ($125,527).
As a Medicare-enrolled provider, Muppidi has provided services to 1,614 Medicare beneficiaries, totaling 2,111 services with total Medicare billing of $177,541. Data is available for 4 years (2020–2023), covering 42 distinct procedure/service records.
Ad
Practice Information
- Specialty Neuromuscular Medicine
- Other Specialties Neurology, Clinical Neurophysiology
- Location Stanford, CA
- Active Since 10/24/2007
- Last Updated 11/10/2023
- Taxonomy Code 2084N0008X
- Entity Type Individual
- NPI Number 1568641736
Products in Payments
- ULTOMIRIS (Drug) $17,446
- SOLIRIS (Drug) $16,849
- VYVGART (Drug) $16,757
- SOLIRIS (Biological) $14,009
- UPLIZNA (Biological) $13,070
- ULTOMIRIS (Biological) $10,408
- NORTHERA (Drug) $4,814
- FIRDAPSE (Drug) $2,525
- UPLIZNA (Drug) $1,800
- Hizentra (Biological) $1,645
- Rystiggo (Drug) $1,600
- TEGSEDI (Drug) $150.00
- SPINRAZA (Biological) $25.67
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Neuromuscular Medicine Doctors in Stanford
Jeffrey Dunn, Md, MD
Neuromuscular Medicine — Payments: $582,888
Neuromuscular Medicine $582,888
Sungho Cho, Md, MD
Neuromuscular Medicine — Payments: $486.57
Neuromuscular Medicine $486.57
Marie Beaudin, Md Msc, MD MSC
Neuromuscular Medicine — Payments: $118.87
Neuromuscular Medicine $118.87
Eric Rider
Neuromuscular Medicine
Neuromuscular Medicine